Education
About Us
Working with TipRanks
Follow Us
Tharimmune (THAR)
NASDAQ:THAR
THAR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.14 - $6.98
Previous CloseN/A
Volume24.91K
Average Volume (3M)126.19K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$3.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.35
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.68
Shares Outstanding2,108,753
10 Day Avg. Volume260,466
30 Day Avg. Volume126,192
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$17.00Price Target Upside1340.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Ownership Overview
8.00% Insiders
0.36% Mutual Funds
2.84% Other Institutional Investors
88.80% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
THAR FAQ
What was Tharimmune’s price range in the past 12 months?
Tharimmune lowest stock price was $1.14 and its highest was $6.98 in the past 12 months.
What is Tharimmune’s market cap?
Currently, no data Available
When is Tharimmune’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tharimmune’s earnings last quarter?
Currently, no data Available
Is Tharimmune overvalued?
According to Wall Street analysts Tharimmune’s price is currently Undervalued.
Does Tharimmune pay dividends?
Tharimmune does not currently pay dividends.
What is Tharimmune’s EPS estimate?
Tharimmune’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tharimmune have?
Tharimmune has 2,108,753 shares outstanding.
What happened to Tharimmune’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tharimmune?
Currently, no hedge funds are holding shares in THAR
---
Company Description
Tharimmune
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
---
THAR Stock 12 Month Forecast
Average Price Target
$17.00
▲(1340.68% Upside)
Technical Analysis
Best Analysts Covering THAR
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-47.70%
initiated a buy rating 4 months ago
Copying Elemer Piros's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -47.70% per trade.
---